Recon: Novartis, Bicycle ink deal valued up to $1.7B to develop targeted radiotherapies; WHO revises COVID-19 vaccine recommendations for Omicron

• Vaccine Decisions: US FDA And CDC Weigh New Vaccines For Diseases From Dengue To RSV (Pink Sheet)
• U.S. FDA panel to discuss Perrigo’s daily OTC birth-control bill in May (Reuters)
• At Tofersen Panel Review, US FDA Shined A Light On Internal Differences Of Opinion (Pink Sheet)
• Drug Supply Chain is Vulnerable to Threats, Says Senate Committee (FDAnews)
• FDA Generics Program Resumes In-Person Meetings (FDAnews)
• Neonatal Drug Development Could Benefit From Rare Disease Experience (Pink Sheet)
• Senator asks FTC to investigate AmerisourceBergen over abortion pill distribution plans (Endpoints)
• As US plots biomanufacturing boost, National Resilience nets $410M loan from Defense Department (Fierce) (Endpoints)
• How the drug industry uses fear of fentanyl to extract more profit from naloxone (STAT)

• WHO revises COVID-19 vaccine recommendations for Omicron-era (Reuters) (WHO)
• Amicus nabs EU nod for Pompe disease newcomer Pombiliti, setting up fight with Sanofi (Fierce)
• WHO Consults On Updates To 24-Year-Old GMP Requirements For Pharma Excipients (Pink Sheet)
• Ukraine needs more prosthetics clinicians as war toll mounts (Reuters)
• Sandoz severs ties with European CMO – Dicillin permanently withdrawn from market  (MedWatch)

• Novartis to ride with Bicycle in radiopharmaceuticals deal that could cruise to $1.7B (Fierce) (BioSpace) (Endpoints)
• BMS re-ups ‘highly productive’ legacy neurodegeneration partnership with Evotec for $50M upfront (Fierce) (BioSpace)
• Eli Lilly to increase investment to $1B into new Irish manufacturing facility — report (Endpoints)
• Sonoma takes ‘a big bite’ with $120M Regeneron Treg collab, tacking on up to 5 new targets (Fierce) (BioPharma Dive)
• Ferring shuts down U.S.-based research institute after more than 25 years, cutting nearly 90 employees (Fierce)
• Boehringer puts $481M on the line to pursue emerging cancer target in Covant team-up (Fierce)
• With another wave of layoffs and CEO exit, AMT seek out ‘strategic alternatives’ (Fierce)
• Merck KGaA takes back control of PD-L1 cancer drug as Pfizer alliance ends (Endpoints)
• Gunning for 2023 approval, GSK details PhIII data for Jemperli in frontline endometrial cancer (Endpoints)
• Australian engineers create ‘flexible robot’ for 3D printing inside the body (Reuters)
• BioNTech readies for plunge in Covid sales, will boost mRNA and oncology pipelines (Endpoints)
• Gamida Cell makes more staff cuts and restructures as it focuses on potential drug launch (Endpoints)
• AbbVie drops CytomX partnership, leaving PhII program in the air (Endpoints)

• Pivotal Opportunity For UK Medtech Must Not Be Wasted (MedTech Insight)
• Getinge heart pump has CE mark suspended by second notified body, halting sales for 3 months (MedTech Dive)
• Wesper Next-Generation Device Cleared for Sleep Test Data Collection (FDAnews)
• Bill would require Medicare to cover breakthrough devices for four years (MedTech Dive)
• Mammography AI maker iCad lays off another 28% of workers as losses grow, revenues shrink (Fierce)
• LSI 2023: What Ophthalmology Start-Ups Pitched To Investors At Emerging Medtech Summit (MedTech Insight)

• Supreme Court Seems Ready To Uphold Ruling Against Amgen’s Anti-PCSK9 Antibody Patents (Pink Sheet)
• Esperion sues Daiichi Sankyo, demanding payment of $300M milestone for cardio drug (Endpoints)
• California Judge Says Zantac Single-Plaintiff Lawsuit May Proceed (FDAnews)
• Buyers of Abbott’s Recalled Baby Formula Cite Economic Harm (Bloomberg)